Article · 4 May 2026
ArticlePublished 17 May 2024
Clinical Effectiveness and Safety of Olprinone Combined with Qiliqiangxin Capsule for Severe Pulmonary Arterial Hypertension and Right Heart Failure
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The present research sets out to elucidate the clinical effectiveness and safety of olprinone combined with qiliqiangxin capsule in the treatment of severe pulmonary arterial hypertension complicated with right heart failure. 55 severe pulmonary arterial hypertension and right heart failure individuals admitted between April 2020 and April 2023 were selected and were assigned as control group (n=25) receiving olprinone treatment while the research group (n=30) received olprinone combined with qiliqiangxin capsules. The clinical effectiveness, safety (rash, chest pain, nausea, vomiting, dizziness, hypotension and tachycardia), echocardiography systolic pulmonary artery pressure, tricuspid annulus plane systolic excursion, right ventricular fractional area change, inferior vena cava collapse index, 6 min walking test and serum N-terminal pro-brain B-type natriuretic peptide were comparatively analyzed. The results showed an evidently higher overall effective rate and a comparable safety profile of the research group compared with the control group. The research group showed markedly reduced systolic pulmonary artery pressure and N-terminal pro-brain B-type natriuretic peptide levels, elevated tricuspid annulus plane systolic excursion, fractional area change, inferior vena cava collapse index and 6 min walking test after treatment, than the control group. Therefore, the combination of olprinone and qiliqiangxin capsule is effective and safe in the treatment of severe pulmonary arterial hypertension+right heart failure patients, which can significantly improve echocardiography results and patients’ exercise ability while exerting a significant inhibitory effect on serum N-terminal pro-brain B-type natriuretic peptide.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Indian Journal of Pharmaceutical Sciences.
Article · 21 Apr 2026
In silico molecular docking analysis of bioactive compounds from Kappaphycus alvarezii and Gracilaria debilis against BRCA1 protein
Article · 11 Mar 2026
Trimethoprim and Sulfamethoxazole-Loaded Nanoparticles Coated With Chitosan for Intranasal Delivery to Treat Cerebral Toxoplasmosis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalIndian Journal of Pharmaceutical Sciences
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “J. Chen”
- BylineArticles whose byline prints “Na Xu”
- BylineArticles whose byline prints “Xuejing Xu”
- BylineArticles whose byline prints “L. Chen”